Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Phase 1 update in Q1 may have too few patients to fully interpret its profile. As such, Monte Rosa shares are likely to be range bound in 2025, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics appoints Hughes to board of directors
- Monte Rosa announces closing of global license agreement with Novartis
- Monte Rosa Therapeutics presents preclinical data on CDK2 degrader
- Monte Rosa Highlights Promising Results in Cancer Study
- Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study